Literature DB >> 11958590

Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels.

Philip E Castle1, Allan Hildesheim, Fredrick P Bowman, Howard D Strickler, Joan L Walker, Terri Pustilnik, Robert P Edwards, Peggy A Crowley-Nowick.   

Abstract

Human papillomavirus (HPV) infects the transformation zone of the cervix and is the primary cause of cervical cancer. The infection is localized to the cervix and mucosal immunity is likely to be an important determinant for viral clearance. Previous studies of immunity to HPV have measured immune markers in the blood, but the relationship of systemic immunity to cervical immunity is poorly understood. In this study of 70 women enrolled in the ASCUS-LSIL Triage Study (ALTS), a clinical trial for management of low-grade cytologic abnormalities of the cervix, we collected paired plasma and cervical secretions to investigate the relationship between cervical concentrations of interleukin-10 (IL-10) and interleukin-12 (IL-12) and plasma levels. Neither IL-10 (p = 0.11), or IL-12 (p = -0.04) nor the ratio of IL-12 to IL-10 (p = 0.06) were correlated between blood and cervical secretions. Except for weak correlations of IL-10 among nonsmokers (p = 0.35. P = 0.019) and those in day 18-27 of their menstrual cycle (p = 0.51, P = 0.015), this lack of correlation persisted in all subgroups defined by genital inflammation or infection, current oral contraceptive use, heme contamination and volume of collected secretions, HPV16 seropositivity, and repeat HPV infection and/or cytologic abnormalities. The lack of correlation and high concentrations in cervical secretions indicate that the cervical IL-10 and IL-12 concentrations exceed what could be expected from blood as a principle source of IL-10 and IL-12 and suggest that cytokine concentrations in cervical secretions are predominantly the result of local cytokine production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11958590     DOI: 10.1023/a:1014252402630

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  14 in total

1.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

2.  Recycling immunoaffinity chromatography for multiple analyte analysis in biological samples.

Authors:  T M Phillips; J M Krum
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-09-11

3.  HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates.

Authors:  H D Strickler; G D Kirk; J P Figueroa; E Ward; A R Braithwaite; C Escoffery; J Drummond; B Goebel; D Waters; R McClimens; A Manns
Journal:  Int J Cancer       Date:  1999-01-29       Impact factor: 7.396

4.  Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures.

Authors:  A Hildesheim; L M McShane; M Schiffman; M C Bratti; A C Rodriguez; R Herrero; L A Morera; F Cardenas; L Saxon; F P Bowman; P A Crowley-Nowick
Journal:  J Immunol Methods       Date:  1999-05-27       Impact factor: 2.303

Review 5.  Type 1/Type 2 immunity in infectious diseases.

Authors:  B Spellberg; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-12-15       Impact factor: 9.079

6.  ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants.

Authors:  M Schiffman; M E Adrianza
Journal:  Acta Cytol       Date:  2000 Sep-Oct       Impact factor: 2.319

7.  Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

Authors:  A H Sarris; K O Kliche; P Pethambaram; A Preti; S Tucker; C Jackow; O Messina; W Pugh; F B Hagemeister; P McLaughlin; M A Rodriguez; J Romaguera; H Fritsche; T Witzig; M Duvic; M Andreeff; F Cabanillas
Journal:  Ann Oncol       Date:  1999-04       Impact factor: 32.976

8.  Levels of interferon-gamma and tumor necrosis factor-alpha in sera and cervical mucus of fertile and infertile women: implication in infertility.

Authors:  R K Naz; A Butler; B R Witt; D Barad; A C Menge
Journal:  J Reprod Immunol       Date:  1995-07       Impact factor: 4.054

9.  Interleukins-6 and -8 levels in sera and cervical mucus of fertile, idiopathic infertile, and immunoinfertile women: implication in infertility.

Authors:  R K Naz; A Butler
Journal:  Am J Reprod Immunol       Date:  1996-06       Impact factor: 3.886

10.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

View more
  16 in total

1.  Genital inflammation and the risk of HIV acquisition in women.

Authors:  Lindi Masson; Jo-Ann S Passmore; Lenine J Liebenberg; Lise Werner; Cheryl Baxter; Kelly B Arnold; Carolyn Williamson; Francesca Little; Leila E Mansoor; Vivek Naranbhai; Douglas A Lauffenburger; Katharina Ronacher; Gerhard Walzl; Nigel J Garrett; Brent L Williams; Mara Couto-Rodriguez; Mady Hornig; W Ian Lipkin; Anneke Grobler; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

2.  Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women.

Authors:  Morgan A Marks; Raphael P Viscidi; Kathryn Chang; Michelle Silver; Anne Burke; Roslyn Howard; Patti E Gravitt
Journal:  Cytokine       Date:  2011-10-19       Impact factor: 3.861

3.  Interleukin (IL)-2 and IL-12 responses to Chlamydia trachomatis infection in adolescents.

Authors:  C Wang; J Tang; P A Crowley-Nowick; C M Wilson; R A Kaslow; W M Geisler
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

4.  Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.

Authors:  Jill Koshiol; Martha Sklavos; Nicolas Wentzensen; Troy Kemp; Mark Schiffman; S Terence Dunn; Sophia S Wang; Joan L Walker; Mahboobeh Safaeian; Rosemary E Zuna; Allan Hildesheim; Ruth M Pfeiffer; Ligia A Pinto
Journal:  Int J Cancer       Date:  2013-07-30       Impact factor: 7.396

5.  Correlates of IL-10 and IL-12 concentrations in cervical secretions.

Authors:  Patti E Gravitt; Allan Hildesheim; Rolando Herrero; Mark Schiffman; Mark E Sherman; M Concepcion Bratti; Ana C Rodriguez; Lidia A Morera; Fernando Cardenas; Frederick P Bowman; Keerti V Shah; Peggy A Crowley-Nowick
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

6.  Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3.

Authors:  Mark E Scott; Yifei Ma; Lili Kuzmich; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

7.  Determinants and correlation of systemic and cervical concentrations of total IgA and IgG.

Authors:  Mahboobeh Safaeian; Troy Kemp; Roni T Falk; Ana Cecilia Rodriguez; Allan Hildesheim; Marcus Williams; Carolina Porras; Rolando Herrero; Ligia A Pinto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10       Impact factor: 4.254

8.  Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions.

Authors:  Philip E Castle; Ana-Cecilia Rodriguez; Frederick P Bowman; Rolando Herrero; Mark Schiffman; M Concepcion Bratti; Lidia Ana Morera; Danny Schust; Peggy Crowley-Nowick; Allan Hildesheim
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

9.  Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates.

Authors:  Jay A Lieberman; Anna-Barbara Moscicki; Jan L Sumerel; Yifei Ma; Mark E Scott
Journal:  Clin Vaccine Immunol       Date:  2007-10-31

10.  CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients.

Authors:  Cinthya E Díaz-Benítez; Karla R Navarro-Fuentes; Jacqueline A Flores-Sosa; Janet Juárez-Díaz; Felipe J Uribe-Salas; Edgar Román-Basaure; Ludwig E González-Mena; Patricia Alonso de Ruíz; Guillermina López-Estrada; Alfredo Lagunas-Martínez; Victor H Bermúdez-Morales; Juan M Alcocer-González; Jesús Martínez-Barnetche; Rogelio Hernández-Pando; Yvonne Rosenstein; José Moreno; Vicente Madrid-Marina
Journal:  J Clin Immunol       Date:  2009-03-04       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.